Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinded randomized placebo-controlled platform study of single investigational treatments in idiopathic pulmonary fibrosis
2021-005066-17Phase 2Active
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing LTP001 with Placebo (2 arms). Primary endpoint: Change in FVC percent predicted from baseline to end of treatment. Started Oct 2022; status: active.
02
Drugs
LTP001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2021-005066-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005066-17.